Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Raymond J, Muller"'
Publikováno v:
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 75(8)
Tall-man (i.e., mixed-case) lettering is used to highlight dissimilarities in look-alike and sound-alike (LASA) drug names.[1][1] Studies have shown that emphasizing definitive sections of drug names using capitalized letters can help distinguish bet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42323cce46eb936463e027626103ac40
https://pubmed.ncbi.nlm.nih.gov/29626001
https://pubmed.ncbi.nlm.nih.gov/29626001
Autor:
Lisa M. Holle, James M. Hoffman, Margaret Sidebottom, Raymond J. Muller, Niesha Griffith, Ali McBride, Colleen Westendorf
Publikováno v:
American Journal of Health-System Pharmacy. 70:609-617
Purpose The results of a survey to characterize oncology drug shortages across the United States and the impact of shortages on clinical practice, patient safety, clinical trials, and health care costs are presented. Methods A 34-item online survey w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd50671fa261df6312955d6f26173cc0
https://doi.org/10.2146/ajhp120563
https://doi.org/10.2146/ajhp120563
Peter B Bach and colleagues call for an end to contradictory regulatory standards in the US that allow drug manufacturers to boost profits by producing single dose vials containing quantities that increase leftover drug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1903f0f6350c67f18183333690e18372
https://europepmc.org/articles/PMC6894487/
https://europepmc.org/articles/PMC6894487/
Autor:
David Baribeault, Raymond J. Muller
Publikováno v:
American Journal of Health-System Pharmacy. 64:2547-2556
Purpose. The safety and efficacy of extended-dosage-interval regimens of erythropoiesis-stimulating agents (ESAs) for managing chemotherapy-induced anemia (CIA) are reviewed. Summary. Anemia is a frequent complication of chemotherapy. The ESAs epoeti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f3b3bdacc5068844ed25db6e6834263
https://doi.org/10.2146/ajhp070018
https://doi.org/10.2146/ajhp070018
Autor:
Ellen Hollywood, Leonard B. Saltz, Diane Lauren Reidy, Ki Y. Chung, Raymond J. Muller, John P. Timoney, Vivian Park, Nancy Sklarin
Publikováno v:
Journal of Clinical Oncology. 25:2691-2695
Purpose Bevacizumab is a humanized monoclonal antibody that targets vascular endothelial growth factor. As a result of concerns for potential infusion-related hypersensitivity reactions (HSRs), initial phase I trials used a 90-, 60-, 30-minute initia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d49489353e043e0d083a4310a74502a6
https://doi.org/10.1200/jco.2006.09.3351
https://doi.org/10.1200/jco.2006.09.3351
Autor:
Lee M. Krug, Mark G. Kris, Vincent A. Miller, Martee L. Hensley, Eileen M. O'Reilly, Raymond J. Muller, Christopher G. Azzoli, Kenneth K.-S. Ng
Publikováno v:
American Journal of Clinical Oncology. 26:247-251
Some degree of peripheral edema occurs in up to 20% of patients treated with gemcitabine (Gemzar). The edema is typically mild, requiring discontinuation of the drug in less than 1% of patients. Most patients require no therapy. However, in cases of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fad4ff8ceb53b9cd29db59c16dd338b0
https://doi.org/10.1097/01.coc.0000017782.24458.dd
https://doi.org/10.1097/01.coc.0000017782.24458.dd
Publikováno v:
Journal of the National Comprehensive Cancer Network : JNCCN. 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c57d29932b27ce467622b0a2970cbd44
https://pubmed.ncbi.nlm.nih.gov/23573552
https://pubmed.ncbi.nlm.nih.gov/23573552
Autor:
Jane M. Pruemer, Richard M. Attilio, Roger W. Anderson, Raymond J. Muller, Michael R. Cohen, Laurence Green
Publikováno v:
American Journal of Health-System Pharmacy. 53:737-746
Recommendations for preventing medication errors in cancer chemotherapy are made. Before a health care provider is granted privileges to prescribe, dispense, or administer antineoplastic agents, he or she should undergo a tailored educational program
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::969fb5bd64f14a5c78eda943de268925
https://doi.org/10.1093/ajhp/53.7.737
https://doi.org/10.1093/ajhp/53.7.737
Autor:
Donna Robinson, Raymond J. Muller, Jennifer De Luca, Stephen Gilheeney, Nancy Sklarin, Jill Ackerman
Publikováno v:
Neuro-Oncology. 18:iii137.6-iii138
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0e67085f37f66084c8bab59bf6c4003
https://doi.org/10.1093/neuonc/now079.16
https://doi.org/10.1093/neuonc/now079.16
Autor:
Lew Iacovelli, Rebecca Arbuckle, Niesha Griffith, Raymond J. Muller, James A. Jorgenson, Dwight D. Kloth, Philip E. Johnson, Charles D. Lucarelli
Publikováno v:
Pharmacotherapy. 28(5 Pt 2)
Erythropoiesis-stimulating agents (ESAs) are approved as an alternative to blood transfusions for treating anemia secondary to chemotherapy in patients with cancer. Recently, ESAs have been a source of controversy and confusion in the oncology commun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eeda36237e6587d0084d897d3c542948
https://pubmed.ncbi.nlm.nih.gov/18447704
https://pubmed.ncbi.nlm.nih.gov/18447704